Lv5
1190 积分 2023-10-24 加入
Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease
1个月前
已完结
Using differential mobility spectrometry to improve the specificity of targeted measurements of 2,3-dinor 11β-Prostaglandin F2α
2个月前
已关闭
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
6个月前
已完结
NO- and Heme-Independent sGC Activators, Runcaciguat and Nurandociguat, as New Treatment Options for CKD: From Bench to Bedside
6个月前
已关闭
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
8个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
8个月前
已完结
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
9个月前
已完结
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
9个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
9个月前
已完结
皖公网安备34019202002308
